Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

New research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Patients regain weight after stopping weight loss drugs, long-term success may depend on lifestyle and drug choice.

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...